{
    "clinical_study": {
        "@rank": "8079", 
        "arm_group": {
            "arm_group_label": "Decitabine, bone marrow transplant", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive decitabine 20 mg/m2 IV for 10 consecutive days.  Beginning 7 - 14 days later, patients will receive 12 Gy total body radiation followed by bone marrow transplant.  GVHD prophylaxis will consist of high dose cyclophosphamide, mycophenolate mofetil, and tacrolimus."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the results of chemotherapy and radiation given before\n      and after a bone marrow transplant from a partially mismatched related donor."
        }, 
        "brief_title": "Decitabine Followed by Partially Matched Related Bone Marrow Transplant for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a Phase II study of decitabine followed by myeloablative conditioning,\n      transplantation of partially HLA-mismatched bone marrow and post-transplantation\n      cyclophosphamide in patients with acute myelogenous leukemia, and high-risk myelodysplastic\n      syndrome."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute myelogenous leukemia\n\n          -  Myelodysplastic syndromes\n\n          -  Available related donor that is at least a high resolution (allele level) haplotype\n             match at HLA A, B, C, DRB1 and DQB1.\n\n        Exclusion Criteria:\n\n          -  Active CNS leukemia within two weeks of registration\n\n          -  New or active infection\n\n          -  Active HIV, hepatitis A, B or C infection\n\n          -  Allergy or hypersensitivity to agents used within the treatment protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707004", 
            "org_study_id": "HO11421"
        }, 
        "intervention": [
            {
                "arm_group_label": "Decitabine, bone marrow transplant", 
                "intervention_name": "Bone marrow transplant", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Decitabine, bone marrow transplant", 
                "intervention_name": "Decitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Decitabine, bone marrow transplant", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Decitabine, bone marrow transplant", 
                "intervention_name": "Mycophenolate mofetil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Decitabine, bone marrow transplant", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Decitabine, bone marrow transplant", 
                "intervention_name": "12 Gy Total body radiation", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Mycophenolate mofetil", 
                "Tacrolimus", 
                "Decitabine", 
                "Mycophenolic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Relapsed", 
            "Refractory"
        ], 
        "lastchanged_date": "June 25, 2013", 
        "location": {
            "contact": {
                "email": "mbj@medicine.wisc.edu", 
                "last_name": "Mark B Juckett, M.D.", 
                "phone": "608-263-0338"
            }, 
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53719"
                }, 
                "name": "University of Wisconsin Hospital and Clinics"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Decitabine Followed by Partially Matched Related Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.", 
        "overall_contact": {
            "email": "mbj@medicine.wisc.edu", 
            "last_name": "Mark B Juckett, M.D.", 
            "phone": "608-263-0338"
        }, 
        "overall_official": {
            "affiliation": "University of Wisconsin, Madison", 
            "last_name": "Mark B Juckett, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to determine overall survival at 100 days after transplantation following decitabine and a HLA-haploidentical bone marrow transplantation using a myeloablative preparative regimen and post-transplantation cyclophosphamide.", 
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "100 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707004"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients enrolled in this study will also be followed for the following endpoints: neutrophil recovery.", 
                "measure": "Neutrophil recovery", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patients enrolled in this study will also be followed for the following endpoints: Graft failure.", 
                "measure": "Assessment of graft failure", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patients enrolled in this study will also be followed for the following endpoints: Acute graft-versus-host disease (GVHD)and chronic GVHD.", 
                "measure": "Asessment of Acute GVHD and Chronic GVHD", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patients enrolled in this study will also be followed for the following endpoints: Incidence of infection.", 
                "measure": "Incidence of infection", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patients enrolled in this study will also be followed for the following endpoints: Treatment-related mortality.", 
                "measure": "Treatment-related mortality", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patients enrolled in this study will also be followed for the following endpoints: platelet recovery.", 
                "measure": "Platelet recovery", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patients enrolled in this study will also be followed for the following endpoints: Time to relapse/progression.", 
                "measure": "Time to relapse/progression", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patients enrolled in this study will also be followed for the following endpoints: Overall survival.", 
                "measure": "Overall patient survival", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patients enrolled in this study will also be followed for the following endpoints: Progression-free survival.", 
                "measure": "Progression-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "University of Wisconsin, Madison", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Wisconsin, Madison", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}